Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
- DOI
- 10.1016/s1470-2045(26)00378-5
- Published
- 2026-11
- Container
- The Lancet Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00378-5,
title = {Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial},
author = {Jian Zhang and Yehui Shi and Qingyuan Zhang and Yiqun Du and Yanchun Meng and Yongsheng Wang and Qiao Cheng and Xin Chen and Zhihua Li and Yongmei Yin and Jie Dong and Juan Zhang and Feifei Wang and Yankui Ou and Petra Rietschel and Claudia-Nanette Gann and Ilhan Celik and Jiong Wu},
year = {2026},
journal = {The Lancet Oncology},
doi = {10.1016/s1470-2045(26)00378-5},
url = {https://doi.org/10.1016/s1470-2045(26)00378-5}
}RIS
TY - JOUR TI - Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial AU - Jian Zhang AU - Yehui Shi AU - Qingyuan Zhang AU - Yiqun Du AU - Yanchun Meng AU - Yongsheng Wang AU - Qiao Cheng AU - Xin Chen AU - Zhihua Li AU - Yongmei Yin AU - Jie Dong AU - Juan Zhang AU - Feifei Wang AU - Yankui Ou AU - Petra Rietschel AU - Claudia-Nanette Gann AU - Ilhan Celik AU - Jiong Wu PY - 2026 JO - The Lancet Oncology DO - 10.1016/s1470-2045(26)00378-5 UR - https://doi.org/10.1016/s1470-2045(26)00378-5 ER -
APA
Zhang, J., Shi, Y., Zhang, Q., Du, Y., Meng, Y., Wang, Y., Cheng, Q., Chen, X., Li, Z., Yin, Y., Dong, J., Zhang, J., Wang, F., Ou, Y., Rietschel, P., Gann, C., Celik, I., & Wu, J. (2026). Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00378-5
Source records
- crossref · retrieved 2026-11-07T06:38:48.606Z